http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 11 Aug 2026 02:52:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>August 11, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, announces the publication of the 'Healthcare Resource Utilization and Costs Associated with Blue Light Versus White Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study' in JU Open Plus this week. The research objective was to evaluate the economic implications of blue light cystoscopy (BLC</b><b>^®</b><b>) versus white light cystoscopy (WLC) with Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> in a real-world setting, using claims data from the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Optum Research Database.</b></p> <p>The study authors described the background as follows: http://www.streetinsider.com/Press+Releases/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html Tue, 11 Aug 2026 02:52:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>August 11, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, announces the publication of the 'Healthcare Resource Utilization and Costs Associated with Blue Light Versus White Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study' in JU Open Plus this week. The research objective was to evaluate the economic implications of blue light cystoscopy (BLC</b><b>^®</b><b>) versus white light cystoscopy (WLC) with Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> in a real-world setting, using claims data from the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Optum Research Database.</b></p> <p>The study authors described the background as follows: http://www.streetinsider.com/Press+Releases/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html Tue, 11 Aug 2026 02:52:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>August 11, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, announces the publication of the 'Healthcare Resource Utilization and Costs Associated with Blue Light Versus White Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study' in JU Open Plus this week. The research objective was to evaluate the economic implications of blue light cystoscopy (BLC</b><b>^®</b><b>) versus white light cystoscopy (WLC) with Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> in a real-world setting, using claims data from the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Optum Research Database.</b></p> <p>The study authors described the background as follows: http://www.streetinsider.com/Press+Releases/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html Tue, 11 Aug 2026 02:52:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>August 11, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, announces the publication of the 'Healthcare Resource Utilization and Costs Associated with Blue Light Versus White Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study' in JU Open Plus this week. The research objective was to evaluate the economic implications of blue light cystoscopy (BLC</b><b>^®</b><b>) versus white light cystoscopy (WLC) with Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> in a real-world setting, using claims data from the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Optum Research Database.</b></p> <p>The study authors described the background as follows: http://www.streetinsider.com/Press+Releases/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html Tue, 11 Aug 2026 02:52:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>August 11, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, announces the publication of the 'Healthcare Resource Utilization and Costs Associated with Blue Light Versus White Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study' in JU Open Plus this week. The research objective was to evaluate the economic implications of blue light cystoscopy (BLC</b><b>^®</b><b>) versus white light cystoscopy (WLC) with Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> in a real-world setting, using claims data from the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Optum Research Database.</b></p> <p>The study authors described the background as follows: http://www.streetinsider.com/Press+Releases/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html Tue, 11 Aug 2026 02:52:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>August 11, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, announces the publication of the 'Healthcare Resource Utilization and Costs Associated with Blue Light Versus White Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study' in JU Open Plus this week. The research objective was to evaluate the economic implications of blue light cystoscopy (BLC</b><b>^®</b><b>) versus white light cystoscopy (WLC) with Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> in a real-world setting, using claims data from the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Optum Research Database.</b></p> <p>The study authors described the background as follows: http://www.streetinsider.com/Press+Releases/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html Tue, 11 Aug 2026 02:52:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/PRNewswire/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>August 11, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, announces the publication of the 'Healthcare Resource Utilization and Costs Associated with Blue Light Versus White Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study' in JU Open Plus this week. The research objective was to evaluate the economic implications of blue light cystoscopy (BLC</b><b>^®</b><b>) versus white light cystoscopy (WLC) with Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> in a real-world setting, using claims data from the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Optum Research Database.</b></p> <p>The study authors described the background as follows: http://www.streetinsider.com/PRNewswire/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html Tue, 11 Aug 2026 02:52:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/PRNewswire/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>August 11, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, announces the publication of the 'Healthcare Resource Utilization and Costs Associated with Blue Light Versus White Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study' in JU Open Plus this week. The research objective was to evaluate the economic implications of blue light cystoscopy (BLC</b><b>^®</b><b>) versus white light cystoscopy (WLC) with Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> in a real-world setting, using claims data from the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Optum Research Database.</b></p> <p>The study authors described the background as follows: http://www.streetinsider.com/PRNewswire/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html Tue, 11 Aug 2026 02:52:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/PRNewswire/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>August 11, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, announces the publication of the 'Healthcare Resource Utilization and Costs Associated with Blue Light Versus White Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study' in JU Open Plus this week. The research objective was to evaluate the economic implications of blue light cystoscopy (BLC</b><b>^®</b><b>) versus white light cystoscopy (WLC) with Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> in a real-world setting, using claims data from the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Optum Research Database.</b></p> <p>The study authors described the background as follows: http://www.streetinsider.com/PRNewswire/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html Tue, 11 Aug 2026 02:52:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/PRNewswire/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>August 11, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, announces the publication of the 'Healthcare Resource Utilization and Costs Associated with Blue Light Versus White Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study' in JU Open Plus this week. The research objective was to evaluate the economic implications of blue light cystoscopy (BLC</b><b>^®</b><b>) versus white light cystoscopy (WLC) with Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> in a real-world setting, using claims data from the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Optum Research Database.</b></p> <p>The study authors described the background as follows: http://www.streetinsider.com/PRNewswire/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html Tue, 11 Aug 2026 02:52:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/PRNewswire/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>August 11, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, announces the publication of the 'Healthcare Resource Utilization and Costs Associated with Blue Light Versus White Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study' in JU Open Plus this week. The research objective was to evaluate the economic implications of blue light cystoscopy (BLC</b><b>^®</b><b>) versus white light cystoscopy (WLC) with Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> in a real-world setting, using claims data from the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Optum Research Database.</b></p> <p>The study authors described the background as follows: http://www.streetinsider.com/PRNewswire/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html Tue, 11 Aug 2026 02:52:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/PRNewswire/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>August 11, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, announces the publication of the 'Healthcare Resource Utilization and Costs Associated with Blue Light Versus White Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study' in JU Open Plus this week. The research objective was to evaluate the economic implications of blue light cystoscopy (BLC</b><b>^®</b><b>) versus white light cystoscopy (WLC) with Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> in a real-world setting, using claims data from the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. Optum Research Database.</b></p> <p>The study authors described the background as follows: http://www.streetinsider.com/PRNewswire/Cost+neutrality+of+BLC+versus+WLC+in+a+real-world+setting+demonstrated+by+new+OPTUM+study+in+the+U.S./26899955.html Tue, 11 Aug 2026 02:52:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ --<b> Photocure ASA </b>(OSE: PHO)<b> today reported Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> revenues of <money>NOK 140.0 million</money> in the second quarter of 2026 (Q2 2025: <money>NOK 135.6 million</money>), and an adjusted EBITDA of <money>NOK 27.2 million</money> (Q2 2025: <money>NOK 27.0 million</money>) for the company. In 2026, <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> expects product revenue growth in the range of 8% to 11% on a constant currency basis and adjusted EBITDA margin expansion.</b></p> <p><i>"<span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> continued to execute well during the second quarter of 2026, delivering sustained commercial momentum across our core business while http://www.streetinsider.com/Press+Releases/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html Wed, 29 Jul 2026 02:25:00 -0400 A.06822034 A.07281921 O.00269804 O.00564781 O.20026344 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ --<b> Photocure ASA </b>(OSE: PHO)<b> today reported Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> revenues of <money>NOK 140.0 million</money> in the second quarter of 2026 (Q2 2025: <money>NOK 135.6 million</money>), and an adjusted EBITDA of <money>NOK 27.2 million</money> (Q2 2025: <money>NOK 27.0 million</money>) for the company. In 2026, <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> expects product revenue growth in the range of 8% to 11% on a constant currency basis and adjusted EBITDA margin expansion.</b></p> <p><i>"<span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> continued to execute well during the second quarter of 2026, delivering sustained commercial momentum across our core business while http://www.streetinsider.com/Press+Releases/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html Wed, 29 Jul 2026 02:25:00 -0400 A.06822034 A.07281921 O.00269804 O.00564781 O.20026344 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ --<b> Photocure ASA </b>(OSE: PHO)<b> today reported Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> revenues of <money>NOK 140.0 million</money> in the second quarter of 2026 (Q2 2025: <money>NOK 135.6 million</money>), and an adjusted EBITDA of <money>NOK 27.2 million</money> (Q2 2025: <money>NOK 27.0 million</money>) for the company. In 2026, <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> expects product revenue growth in the range of 8% to 11% on a constant currency basis and adjusted EBITDA margin expansion.</b></p> <p><i>"<span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> continued to execute well during the second quarter of 2026, delivering sustained commercial momentum across our core business while http://www.streetinsider.com/Press+Releases/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html Wed, 29 Jul 2026 02:25:00 -0400 A.06822034 A.07281921 O.00269804 O.00564781 O.20026344 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ --<b> Photocure ASA </b>(OSE: PHO)<b> today reported Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> revenues of <money>NOK 140.0 million</money> in the second quarter of 2026 (Q2 2025: <money>NOK 135.6 million</money>), and an adjusted EBITDA of <money>NOK 27.2 million</money> (Q2 2025: <money>NOK 27.0 million</money>) for the company. In 2026, <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> expects product revenue growth in the range of 8% to 11% on a constant currency basis and adjusted EBITDA margin expansion.</b></p> <p><i>"<span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> continued to execute well during the second quarter of 2026, delivering sustained commercial momentum across our core business while http://www.streetinsider.com/Press+Releases/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html Wed, 29 Jul 2026 02:25:00 -0400 A.06822034 A.07281921 O.00269804 O.00564781 O.20026344 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ --<b> Photocure ASA </b>(OSE: PHO)<b> today reported Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> revenues of <money>NOK 140.0 million</money> in the second quarter of 2026 (Q2 2025: <money>NOK 135.6 million</money>), and an adjusted EBITDA of <money>NOK 27.2 million</money> (Q2 2025: <money>NOK 27.0 million</money>) for the company. In 2026, <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> expects product revenue growth in the range of 8% to 11% on a constant currency basis and adjusted EBITDA margin expansion.</b></p> <p><i>"<span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> continued to execute well during the second quarter of 2026, delivering sustained commercial momentum across our core business while http://www.streetinsider.com/Press+Releases/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html Wed, 29 Jul 2026 02:25:00 -0400 A.06822034 A.07281921 O.00269804 O.00564781 O.20026344 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ --<b> Photocure ASA </b>(OSE: PHO)<b> today reported Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> revenues of <money>NOK 140.0 million</money> in the second quarter of 2026 (Q2 2025: <money>NOK 135.6 million</money>), and an adjusted EBITDA of <money>NOK 27.2 million</money> (Q2 2025: <money>NOK 27.0 million</money>) for the company. In 2026, <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> expects product revenue growth in the range of 8% to 11% on a constant currency basis and adjusted EBITDA margin expansion.</b></p> <p><i>"<span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> continued to execute well during the second quarter of 2026, delivering sustained commercial momentum across our core business while http://www.streetinsider.com/Press+Releases/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html Wed, 29 Jul 2026 02:25:00 -0400 A.06822034 A.07281921 O.00269804 O.00564781 O.20026344 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ --<b> Photocure ASA </b>(OSE: PHO)<b> today reported Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> revenues of <money>NOK 140.0 million</money> in the second quarter of 2026 (Q2 2025: <money>NOK 135.6 million</money>), and an adjusted EBITDA of <money>NOK 27.2 million</money> (Q2 2025: <money>NOK 27.0 million</money>) for the company. In 2026, <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> expects product revenue growth in the range of 8% to 11% on a constant currency basis and adjusted EBITDA margin expansion.</b></p> <p><i>"<span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> continued to execute well during the second quarter of 2026, delivering sustained commercial momentum across our core business while http://www.streetinsider.com/Press+Releases/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html Wed, 29 Jul 2026 02:25:00 -0400 A.06822034 A.07281921 O.00269804 O.00564781 O.20026344 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ --<b> Photocure ASA </b>(OSE: PHO)<b> today reported Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> revenues of <money>NOK 140.0 million</money> in the second quarter of 2026 (Q2 2025: <money>NOK 135.6 million</money>), and an adjusted EBITDA of <money>NOK 27.2 million</money> (Q2 2025: <money>NOK 27.0 million</money>) for the company. In 2026, <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> expects product revenue growth in the range of 8% to 11% on a constant currency basis and adjusted EBITDA margin expansion.</b></p> <p><i>"<span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> continued to execute well during the second quarter of 2026, delivering sustained commercial momentum across our core business while http://www.streetinsider.com/Press+Releases/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html Wed, 29 Jul 2026 02:25:00 -0400 A.06822034 A.07281921 O.00269804 O.00564781 O.20026344 OSAKA PHO PHO http://www.streetinsider.com/PRNewswire/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ --<b> Photocure ASA </b>(OSE: PHO)<b> today reported Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> revenues of <money>NOK 140.0 million</money> in the second quarter of 2026 (Q2 2025: <money>NOK 135.6 million</money>), and an adjusted EBITDA of <money>NOK 27.2 million</money> (Q2 2025: <money>NOK 27.0 million</money>) for the company. In 2026, <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> expects product revenue growth in the range of 8% to 11% on a constant currency basis and adjusted EBITDA margin expansion.</b></p> <p><i>"<span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> continued to execute well during the second quarter of 2026, delivering sustained commercial momentum across our core business while http://www.streetinsider.com/PRNewswire/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html Wed, 29 Jul 2026 02:25:00 -0400 A.06822034 A.07281921 O.00269804 O.00564781 O.20026344 OSAKA PHO PHO http://www.streetinsider.com/PRNewswire/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ --<b> Photocure ASA </b>(OSE: PHO)<b> today reported Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> revenues of <money>NOK 140.0 million</money> in the second quarter of 2026 (Q2 2025: <money>NOK 135.6 million</money>), and an adjusted EBITDA of <money>NOK 27.2 million</money> (Q2 2025: <money>NOK 27.0 million</money>) for the company. In 2026, <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> expects product revenue growth in the range of 8% to 11% on a constant currency basis and adjusted EBITDA margin expansion.</b></p> <p><i>"<span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> continued to execute well during the second quarter of 2026, delivering sustained commercial momentum across our core business while http://www.streetinsider.com/PRNewswire/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html Wed, 29 Jul 2026 02:25:00 -0400 A.06822034 A.07281921 O.00269804 O.00564781 O.20026344 OSAKA PHO PHO http://www.streetinsider.com/PRNewswire/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ --<b> Photocure ASA </b>(OSE: PHO)<b> today reported Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> revenues of <money>NOK 140.0 million</money> in the second quarter of 2026 (Q2 2025: <money>NOK 135.6 million</money>), and an adjusted EBITDA of <money>NOK 27.2 million</money> (Q2 2025: <money>NOK 27.0 million</money>) for the company. In 2026, <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> expects product revenue growth in the range of 8% to 11% on a constant currency basis and adjusted EBITDA margin expansion.</b></p> <p><i>"<span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> continued to execute well during the second quarter of 2026, delivering sustained commercial momentum across our core business while http://www.streetinsider.com/PRNewswire/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html Wed, 29 Jul 2026 02:25:00 -0400 A.06822034 A.07281921 O.00269804 O.00564781 O.20026344 OSAKA PHO PHO http://www.streetinsider.com/PRNewswire/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ --<b> Photocure ASA </b>(OSE: PHO)<b> today reported Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> revenues of <money>NOK 140.0 million</money> in the second quarter of 2026 (Q2 2025: <money>NOK 135.6 million</money>), and an adjusted EBITDA of <money>NOK 27.2 million</money> (Q2 2025: <money>NOK 27.0 million</money>) for the company. In 2026, <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> expects product revenue growth in the range of 8% to 11% on a constant currency basis and adjusted EBITDA margin expansion.</b></p> <p><i>"<span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> continued to execute well during the second quarter of 2026, delivering sustained commercial momentum across our core business while http://www.streetinsider.com/PRNewswire/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html Wed, 29 Jul 2026 02:25:00 -0400 A.06822034 A.07281921 O.00269804 O.00564781 O.20026344 OSAKA PHO PHO http://www.streetinsider.com/PRNewswire/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ --<b> Photocure ASA </b>(OSE: PHO)<b> today reported Hexvix</b><b>^®</b><b>/Cysview</b><b>^®</b><b> revenues of <money>NOK 140.0 million</money> in the second quarter of 2026 (Q2 2025: <money>NOK 135.6 million</money>), and an adjusted EBITDA of <money>NOK 27.2 million</money> (Q2 2025: <money>NOK 27.0 million</money>) for the company. In 2026, <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> expects product revenue growth in the range of 8% to 11% on a constant currency basis and adjusted EBITDA margin expansion.</b></p> <p><i>"<span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span> continued to execute well during the second quarter of 2026, delivering sustained commercial momentum across our core business while http://www.streetinsider.com/PRNewswire/Photocure+ASA%3A+Results+for+the+second+quarter+of+2026/26828904.html Wed, 29 Jul 2026 02:25:00 -0400 A.06822034 A.07281921 O.00269804 O.00564781 O.20026344 OSAKA PHO PHO